CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zymergen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zymergen Inc
1440 Stanford Avenue
Phone: (415) 801-8073p:415 801-8073 EMERYVILLE, CA  94608  United States Fax: (302) 655-5049f:302 655-5049
This company's Plan of Liquidation went into effect on 2/23/2024
This company was Merged or Acquired on 10/19/2022.
This company ceased filing statements with the SEC on 10/31/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Zymergen Inc. integrates computational and manufacturing technologies to design, develop, and commercialize bio-based products in a range of industries. Its platform consists of three key capabilities: its collection of accessible biomolecules; its software and data science technology, and its data-driven microbe optimization processes. Its businesses include advanced materials, which seeks to employ bio-advantaged molecules or microbes to develop and deliver products and is focused on four markets: agriculture, water repellency, advanced polymers, and healthcare; drug discovery business leverages its differentiated access to natural products as a source of diverse chemical matter provided by its unified metagenomics database, and automation business, which offers automation technology to organizations involved in lab operations. Its software and data science platform informs, guides, and records its experiments forming the infrastructure for the learning cycle.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYesYes-Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
2671 Packaging paper and plastics film, coated and laminated
2879 Pesticides and agricultural chemicals, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Acting Chief Executive Officer Jay T.Flatley 69 8/1/2021 1/1/2020
Chief Financial Officer EnakshiSingh 43 2/24/2021 8/1/2014
Chief Manufacturing Officer Aindrea M.Campbell 5/4/2021 5/4/2021
13 additional Officers and Directors records available in full report.

Business Names
Business Name
1776 Pharmaceuticals LLC
Enevolv, Inc.
enVolv, Inc.
8 additional Business Names available in full report.

General Information
Outstanding Shares: 104,355,336 (As of 8/31/2022)
Shareholders: 89
Stock Exchange: NASD
Federal Tax Id: 462942439
Fax Number: (302) 655-5049
Email Address: info@zymergen.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024